AMERICAN FORK, Utah--(BUSINESS WIRE)--Xlear Inc. is proud to share the first results of the ongoing clinical trials using Xlear nasal spray as an adjunct treatment for people that have been exposed to Sars-cov-2. Several InVitro studies over the past few months have shown that Xlear nasal spray is extremely effective at both blocking viral adhesion of the Sars-cov-2 and also destroying the virus. Xlear is an over-the-counter (OTC) nasal spray that has been on the market both in the United States and abroad for more than two decades and is available at most pharmacies, grocery stores and online.
The paper published last week has shown very promising results. It is the first paper published with regards to actual human clinical trials. In short, within days of starting to use the nasal spray the patients have become asymptomatic, and within 7 days they are testing negative by PCR. All of the patients in the trials have symptoms, have tested positive by PCR, and also have underlying health conditions.
The clinical trials are ongoing however with a twenty-year safety record Xlear is hoping that people can start using the Xlear nasal spray as an adjunct to other safety measures such as wearing a mask and social distancing.
The published paper can be read here:
Both Xlear CEO & Founder Nathan Jones and Dr. Gustavo Ferrer, an acclaimed pulmonologist and former WHO infectious disease researcher that has been running two ICUs in Miami and a Covid subject matter expert for most national media outlets are available for interviews or to provide any additional information.
